Researchers analyzed 27 different studies to see how well gut microbiome biomarkers could detect colorectal cancer and adenoma cases. The analysis found that these markers showed a high level of accuracy in distinguishing between healthy individuals and those with cancer. Specific bacteria, such as Fusobacterium nucleatum and Parvimonas micra, were consistently more common in patients with cancer, while others like Roseburia spp. were less common.
A key finding was the impact of age on these tests. The results showed that the accuracy of the test improved when there was a larger age difference between the group of people with cancer and the healthy control group. Other factors, such as body mass index (BMI) and the ratio of women in the study groups, did not change how well the markers performed.
It is important to note that some individual studies were small, which can sometimes make a test look more accurate than it might be in a larger population. Because these findings come from a collection of different studies with varying methods, they are not yet ready to replace standard screenings. Patients should talk to their doctor about how these emerging markers might fit into their personal health plan.
